MedTrace Logo

Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer

NCT04913532 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-01-23

No results posted yet for this study

Summary

Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer.

Investigators initiated this phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer.

Conditions

Interventions

RADIATION

Hypofractionation with simultaneous integrated boost

Hypofractionation with simultaneous integrated boost

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Wenjie Ni, MD. · Beijing Shijitan Hospital, Capital Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-22
Primary Completion
2023-06-30
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913532 on ClinicalTrials.gov